- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01999712
Right Ventricular Failure After Implantation of Left Ventricular Assist Devices
The left ventricular assist device (LVAD) is a portable mechanical pump that helps the left side of the heart of patients with severe heart failure that are awaiting heart transplantation or are not transplant candidates. However, while LVAD supports the left side of the heart, the right side must work on its own. Sometimes the right side does not recover, a condition called right ventricular failure (RVF). This complication increases mortality, prolongs hospitalization, requires additional procedures, and increases costs. Several risk factors and scores have been proposed to identify patients at risk for RVF. However, these methods have proven inadequate; one out of three patients is still experiencing right ventricular failure after LVAD surgery.
Echocardiography, an established noninvasive method to see the heart without radiation or risk, has a lot of potential to identify patients at risk for RVF. The questions we will tray to answer with this American Heart Association funded project are:
- Can echocardiography before scheduled LVAD surgery predict who is going to develop RVF and poor quality of life so we can better select patients for LVAD surgery?
- Can echocardiography before scheduled LVAD surgery tell us the course of right ventricular function after implantation so we can potentially take additional measures and prevent RVF?
To answer these questions, we will record images of the heart with echocardiography before LVAD surgery in 120 LVAD recipients at Emory University. We will then follow the patients for 90 days to detect any symptoms and signs of clinical RVF and poor quality of life and record the course of right ventricular function with echocardiography.
Currently, it is estimated that 150,000 to 250,000 patients in US are potential LVAD recipients with 2,000 devices implanted in 2012. LVAD can improve survival and quality of life in suitable patients. However, implantation requires a major surgical procedure with associated risks and considerable resources. Thus, careful patient selection is necessary to minimize risk for patients and maximize benefit for patients and society. Our long-term goal is to use echocardiography as a tool to (1) optimally select patients for LVAD and offer alternatives to patients at increased risk for complications and (2) potentially, inform earlier LVAD implantation in patients with weakening right ventricular function.
Study Overview
Detailed Description
Despite (1) improved outcomes and lower rates of right ventricular failure (RVF) with the newer, continuous-flow left ventricular assist devices (LVAD) over pulsatile-flow devices and (2) development of clinical prediction scores to identify patients at risk for RVF post LVAD, RVF still occurs in 20% to 40% of recipients, even with the newer devices.
In 2012, 2000 LVADs were implanted in U.S. and the number is rapidly increasing. Post-LVAD outcomes depend critically on right ventricular (RV) function. RVF can lead to:
- Reduced survival and progression to transplant (Tx) and worse post-Tx outcomes
- Significantly higher rates of resources utilization
- Long-term poor exercise capacity and quality of life (QoL)
True echocardiographic quantification of RV function has only recently been considered in RVF prediction post LVAD; however these studies were retrospective and had inconsistent population and outcome definitions. Also, despite promising results in a retrospective study, preoperative RV mechanics have not been prospectively evaluated as RVF predictors to date.
In this study, we plan to enroll a total of 120 LVAD candidates to evaluate standard and mechanics-based echocardiographic measures of RV function for prediction of (1) RVF within 90 days; (2) QoL at 90 days; and (3) RV recovery at 90 days post LVAD implantation.
Aim 1: We will perform echocardiography within 7 days of planned LVAD surgery to evaluate the association of prespecified RV parameters with (1) RVF within 90 days and (2) QoL at 90 days. Our main hypotheses is an RV echo score will predict RVF within 90 days post LVAD with clinically relevant discrimination (C>0.85) and positive and negative predictive values (>80%). Our secondary hypothesis is that the RV score will predict poor QoL at 90 days with clinically relevant discrimination and predictive values.
Aim 2: We will repeat echocardiograms at 30 and 90 days post LVAD surgery to examine the association of baseline RV function with RV recovery. Our hypothesis is that the RV score will predict RV function recovery post LVAD and that RV mechanics will have incremental value for prediction of these outcomes.
These results may help improve LVAD outcomes and reduce resource utilization by facilitating shared decision-making and selection for LVAD vs. alternatives; provide insights into RV function recovery; and inform reassessment of LVAD timing.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-75 years
- Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Class 2-7
- Willing to participate
- Able to give consent
Exclusion Criteria:
- INTERMACS Class 1
- Pre-operative advanced RVF, defined as planned or anticipated need for RVAD or extracorporeal membrane oxygenation at surgery
- Unresponsive pulmonary vascular resistance (PVR) >6 Wood units
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
LVAD recipients
Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
|
Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Right ventricular failure
Time Frame: 90 days
|
Right ventricular failure (RVF) at 90 days, defined as RVF-related death (multi-organ failure), need for inhaled nitric oxide postoperatively for ≥48h, need for post-operative inotropes for ≥14 days, reinstitution of inotropes beyond 14 days, or need for a RV assist device (RVAD)
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life
Time Frame: 90 days
|
QoL by Kansas City Cardiomyopathy Questionnaire at 90 days defined as summary score <45
|
90 days
|
Right ventricular recovery
Time Frame: 30 and 90 days
|
RV recovery, defined as 5% improvement in RV fractional area change at 30 days and 90 days
|
30 and 90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andreas P Kalogeropoulos, MD, PhD, Emory University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00058588
- 13SDG15960001 (Other Identifier: Other)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Echocardiography
-
Kang YanRecruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
-
Assiut UniversityUnknownCORONARY ARTERY BYPASSEgypt
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityUnknownMyocardial Infarction | Left Ventricular Dysfunction | Echocardiography 2DEgypt
-
Milton S. Hershey Medical CenterCompletedEchocardiography, Transesophageal | Ventricular Function, RightUnited States
-
Weill Medical College of Cornell UniversityWithdrawn3D Transesophageal and Transthoracic EchocardiogramUnited States
-
London North West Healthcare NHS TrustRecruitingCoronary Artery DiseaseUnited Kingdom
-
Papworth Hospital NHS Foundation TrustUnknownChronic Thromboembolic Pulmonary Hypertension
-
Assiut UniversityNot yet recruiting